Cargando…

The Role of High-Density Lipoprotein Cholesterol in 2022

PURPOSE OF THE REVIEW: High-density lipoproteins (HDL) are responsible for the transport in plasma of a large fraction of circulating lipids, in part from tissue mobilization. The evaluation of HDL-associated cholesterol (HDL-C) has provided a standard method for assessing cardiovascular (CV) risk,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sirtori, Cesare R., Corsini, Alberto, Ruscica, Massimiliano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Statin Drugs (R. Ceska, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913032/ https://www.ncbi.nlm.nih.gov/pubmed/35274229 http://dx.doi.org/10.1007/s11883-022-01012-y

Ejemplares similares

Lipid Lowering Drugs: Present Status and Future Developments
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia
por: Pang, Jing, et al.
Publicado: (2020)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents
por: Cohen, Hofit, et al.
Publicado: (2021)

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
por: Martin, Anna, et al.
Publicado: (2022)

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
por: Altschmiedová, Tereza, et al.
Publicado: (2022)

PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
por: Carugo, Stefano, et al.
Publicado: (2022)

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
por: Lorgelly, Paula K., et al.
Publicado: (2010)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
por: Strandberg, Timo E.
Publicado: (2019)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

A Review of the Rationale for Additional Therapeutic Interventions to Attain Lower LDL-C When Statin Therapy Is Not Enough
por: Shanes, Jeffrey G.
Publicado: (2011)

Statin Intolerance: the Clinician’s Perspective
por: Stulc, Tomáš, et al.
Publicado: (2015)

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
por: Lee, Matthew M. Y., et al.
Publicado: (2019)

Role of lipoprotein(a) in plaque progression
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Clinical approach to the inflammatory etiology of cardiovascular diseases
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis
por: Ruscica, Massimiliano, et al.
Publicado: (2019)

Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Meroni, Marica, et al.
Publicado: (2021)

Cardiovascular risk and testosterone – from subclinical atherosclerosis to lipoprotein function to heart failure
por: Gencer, Baris, et al.
Publicado: (2021)

Worsening of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in patients with prostate cancer after androgen deprivation therapy
por: Oka, Ryo, et al.
Publicado: (2018)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Long-term fasting improves lipoprotein-associated atherogenic risk in humans
por: Grundler, Franziska, et al.
Publicado: (2021)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Visit-to-visit variability in low-density lipoprotein cholesterol
por: Sookaromdee, Pathum, et al.
Publicado: (2019)

Comparison of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol for the prediction of thin-cap fibroatheroma determined by intravascular optical coherence tomography
por: WANG, Yao, et al.
Publicado: (2020)

Total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol as predictors of coronary artery calcification assessed by multidetector computed tomography coronary angiography
por: Elsadek Seaoud, Elshaimaa Aly M., et al.
Publicado: (2022)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Comment on “Role of monocyte to high-density lipoprotein cholesterol ratio in predicting left atrial enlargement in hypertensive patients”
por: Qiu, Like, et al.
Publicado: (2022)

High-density lipoprotein cholesterol: How High
por: Rajagopal, G., et al.
Publicado: (2012)

High-Density Lipoproteins and Serum Amyloid A (SAA)
por: Webb, Nancy R.
Publicado: (2021)

The role of free triiodothyronine in high-density lipoprotein cholesterol metabolism
por: Huang, Fang, et al.
Publicado: (2019)

Role of High‐Density Lipoproteins in Cholesterol Homeostasis and Glycemic Control
por: Manandhar, Bikash, et al.
Publicado: (2019)

Utility of Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Evaluating Incident Diabetes Risk
por: Sheng, Guotai, et al.
Publicado: (2022)

Assessment of serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in periodontitis patients
por: Penumarthy, Swati, et al.
Publicado: (2013)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l3iko6jsl3n8k5pqgs0ttvp6ir